ATRX and acute myeloid leukemia: Additionally, treatment for 2 weeks with the two agents compared to vehicle control also significantly reduced AML burden in an AML PDX mtNPM1-FLT3-ITD model, which also harbored mutations in FLT3-TKD D835Y, PHF6 and ATRX (Figs. 7B, C, and Table S3).